The purpose of this study was to determine if a cytoreductive agent could provide additional efficacy to treat blood hyperviscosity.
Among adult patients with newly diagnosed AML, the presence of an FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Administering MD-MTX prophylaxis against CNS relapse of DLBCL appeared best as early as possible or following R-CHOP completion.
Modifications of ABVD or CHOP were common among elderly patients with cHL and may contribute to their disproportionate excess mortality, signaling a need for less toxic regimens.
In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.
Inotuzumab ozogamicin instead of gemcitabine added to R-CVP did not improve OS or PFS, but less toxicity among patients with untreated DLBCL with comorbid conditions.